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Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S139The aim of our study was to review toxicities related to the
continuation of cART during chemotherapy in HIV-infected
patients undergoing autologous stem cell transplants (ASCT)
for haematological malignancies.
This was a retrospective study, which included HIV-
infected patients who were on cART and underwent ASCT
for a haematological malignancy from January 1st 2003 to
December 31st 2013 at a single institution. We reviewed
adverse effects related to the use cART during conditioning
chemotherapy.
A total of 11 patients were included, n¼1 acute myeloid
leukemia (AML), n¼4 multiple myeloma (MM), n¼4 Burkitt
lymphoma, n¼1 plasmablastic lymphoma, n¼1 primary
effusion lymphoma and n¼1 Hodgkin lymphoma. Of the 11
patients, 6 (54%) were on non-Protease inhibitor (PI) and 5
(56%) were on PI based cART during their transplant. NoTRM
were observed; all patients continued cART during
conditioning chemotherapy. 6 Patients relapsed, 2 were
salvaged by allogeneic HSCT, and 2 MM patients were given
salvage treatment. There were 5 non-treatment related
deaths, n¼1 developed secondary malignancy, n¼1 relapsed
AML, n¼2 relapsed MM and one patient died due to
zidovudine induced lactic acidosis 10 months post ASCT.
Overall survival from ranged from 1-8 yrs.
This case series demonstrated that concomitant use of
cART during conditioning chemotherapy for patients
undergoing ASCT does not adversely affect treatment
outcomes. Therefore, we recommend continuing cART
during ASCT. However, we recommend avoiding zidovudine
during conditioning chemotherapy due to high risk of
myelosuppression.Figure 1. Progression free in survival among Caucasian patients compared to
African American patients during the 24-month follow-up period (Log Rank¼
0.03).157
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Background: The incidence of CMV after ASCT is much lower
(1-9%) than after allogeneic transplantation. However, with
recent use of R, there has been increasing concern about
opportunistic infections. The objective of our study was to
determine the disease burden and characteristics of CMV
infection/reactivation after ASCT in recent years.
Methods: Records were searched in Karmanos Cancer Center
database for the occurrence of CMV infection/disease during
the post-transplantation period in patients undergoing ASCT
between December 2007 and December 2013. Charts were
reviewed retrospectively to identify characteristics of CMV
infection/reactivation/disease, demographic features and
outcomes of the affected patients.
Results: Seven of 978 ASCT recipients {multiple myeloma
(MM): 601 patients (pts), non-Hodgkins lymphoma (NHL):
252 pts, Hodgkins lymphoma (HD): 99 pts} were found to be
viremic by CMV PCR within the ﬁrst 3 months after trans-
plant, during work up for antibiotic-resistant fever. The
median time for development of CMV PCR positive status
was 33 days post-transplantation (range, 18e78 days). CMV
viremia developed in 3 of the 236 patients who received R
with induction or preparative regimens as compared to 4 of
742 who did not receive R (p¼0.2). In all 7 patients, viremia
developed after neutrophil engraftment.
Of the 7 patients, 3 developed bacterial and/or fungal
infection within 60 days from onset of viremia. Median levelof CMV viremia was 16,912 copies/ml (range, 724e33,100) in
these 3 patients. All 3 patients received anti-viral and other
appropriate anti-microbial therapy. The viremia resolved in a
median of 17.5 days (range, 9e26 days). One of these patients
died at 28 days from onset of CMV viremia due to invasive
candidiasis and septic shock.
The remaining 4 patients, who did not develop bacterial
or fungal infection within 60 days from viremia, had median
CMV copies/ml of 700 (range, 250e1707). Only one of these
4 patients received anti-CMV therapy but he died shortly,
thereafter (at 19 days from onset of viremia), due to pro-
gression of primary malignancy.
None of the 7 patients had documented evidence of tissue
invasive CMV disease.
Conclusion: Despite the use of R prior to ASCT, frequency of
CMV infection/disease remains low in this population. Low
level of CMV viremia does not appear to warrant therapy.
Higher levels of viremia were associated with development
of subsequent bacterial/fungal infections.158
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Background: Upfront ASCT in eligible patients (pts) is
currently considered a standard of care and has been shown
to improve disease free survival and overall survival (OS) in
randomized trials. The incidence of MM in AA population is
twice compared to the Caucasian (C) population and the
mortality rates are higher in AA pts with MM. The plausible
reasons for this are higher incidence of poor risk disease, less
upfront exposure to novel agents, lower referral rate for ASCT
and poor access to health care. The aim of our study is to
identify differences in clinical characteristics and outcomes
in two groups.
Methods: We performed a retrospective analysis in MM pts
who underwent ASCT at Karmanos Cancer Center between
Figure 2. Overall survival among Caucasian patients compared to African
American patients during the 24-month follow-up period (Log Rank¼0.25).
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variables between the two groups were assessed using stu-
dent t-test andWilcox log rank sum test; Chi-square test was
used for categorical variables. Kaplan Meier curves were
performed to assess survival and disease progression over
time.
Results: During this time 92 AA and 317 C patients under-
went ASCT. Median follow-up was 721 days in AA (IQR,
392e1103) versus (vs.) 735 days in C (IQR, 375e1124). The
mean age of AA at time of transplant was signiﬁcantly lower
than that of Caucasian pts (55.67 8 years vs. 57.74 8 years,
p¼ .032). Durie-Salmon stage distributionwas similar in two
groups with about 60% of patients in stage III at diagnosis.
Cytogenetic risk distribution was similar in two groups: (AA
vs. C) standard risk 82% vs. 86%; intermediate risk 16% vs.
10%, p ¼ 0.17; high risk 1.5% vs. 4%, p ¼ 0.34. Disease status at
the time of transplant was CR in 8% AA vs. 21% C (p¼0.03),
VGPR in 42% AA vs. 29% C (p¼0.66) and PR in 34% AA vs. 33%
C. The median time from diagnosis to ASCT in AA was
signiﬁcantly longer than that for C {288 days; IQR
(216.75e677.50) vs. 213 days; IQR (173.50e371.50), p¼
<0.001}. Induction therapy prior to transplant consisted of
novel agent (proteasome inhibitor and/or immunomodula-
tory agent) based regimens in all patients. Median number of
cycles of induction therapy was 5 (range 4-16) vs. 4 (range 3-
22) cycles in AA vs. C. Preparative regimen for ASCT was
Melphalan 140mg/m2 in 31% vs. 26% (AA vs. C) and
Melphalan 200mg/m2 in the rest. Rate of disease progression
after two-year median follow-up was higher in the AA pts
39% vs. 27%, OR 1.75 (1.08-2.85), p ¼ 0.02 (Figure 1). There
was no difference in the overall survival in two groups
after median follow-up of two years 86% vs. 90%, OR 1.47
(0.73e2.93) p ¼ 0.27 (Figure 2).
Conclusion: AA pts are diagnosed with MM at a younger age
as compared with C population. Time from diagnosis of MM
to referral to ASCT in the AA patients is longer than in the C.
In addition, the rate of disease progression post-ASCT is
higher in AA pts.159
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Introduction: Mantle cell lymphoma (MCL) is a rare B-cell
malignancy comprising 5-10% of all non-Hodgkin lymphoma
cases. Autologous hematopoietic stem cell transplant has
emerged as a viable therapy for many patients with MCL. An
important step in the harvesting of peripheral blood he-
matopoietic stem cells (HSC) is mobilizing CD34+ HSC to the
peripheral blood. The novel compound plerixafor is an
antagonist of CXCR4, and has been successful in mobilization
of HSC for autologous stem cell transplants for non-Hodgkin
lymphoma. Increased mobilization of HSC in peripheral
blood carries the risk of increased mobilization of lymphoma
cells. Since MCL expresses CXCR4, we sought to determine
whether administration of plerixafor can adversely affect
outcome in transplantation. We report survival results of
autologous peripheral blood stem cell transplants (ASCT) for
patients with MCL who were treated with and without
plerixafor for HSC mobilization prior to ASCT at Mayo Clinic.
Methods: The present study is a retrospective cohort study
of all adult patients who underwent ASCT for treatment of
MCL at Mayo Clinic from February 1993 to December 2013.
Patients were divided into two cohorts: (1) patients treated
with plerixafor for HSC mobilization prior to ASCT, and (2)
patients not treated with plerixafor prior to ASCT. The pri-
mary outcome was relapse of MCL. Overall survival from
diagnosis and overall survival from transplant were also
analyzed.
Patients: From 1993 to 2013, 169 consecutive patients un-
derwent ASCT; 55 patients received plerixafor for HSC
mobilization prior to ASCT, and 114 patients did not receive
plerixafor. The median ages at MCL diagnosis and ASCT for
the plerixafor cohort were 57.7 years and 58.4 years,
respectively, compared with 56.6 years and 58.1 years for the
non-plerixafor cohort.
Results: The average CD34+ HSC harvest with plerixafor was
5.4  106/kg compared to 4.9  106/kg without plerixafor (p
¼ 0.13). Median progression-free survival from ASCT was 3.4
years in the plerixafor cohort compared with 3.6 years in the
non-plerixafor cohort (p ¼ 0.69). Median overall survival
from ASCT was not reached in the plerixafor cohort
compared with 5.7 years in the non-plerixafor cohort (p ¼
0.95). Median overall survival from MCL diagnosis was 8.9
years in the plerixafor cohort compared with 7.6 years in the
non-plerixafor cohort (p ¼ 0.71).
Conclusions: ASCT for treatment of MCL performed at Mayo
Clinic resulted in no statistically signiﬁcant differences in
progression-free and overall survival between patients
receiving and patients not receiving plerixafor for CD34+HSC
mobilization prior to ASCT. The results of this study indicate
that HSC mobilization using plerixafor is not associated with
decreased progression-free or overall survival from ASCT in
MCL. There appears to be no clinically signiﬁcant mobiliza-
tion of lymphoma cells associated with plerixafor mobiliza-
tion of HSC.160
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Secondary engraftment failure is deﬁned as neutrophils
increase to  0.5 x 10 ⁹/L and subsequently decrease to a
lower level until additional treatment to obtain
